SEC FORM 3SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Freeburg Thomas John

(Last)(First)(Middle)
C/O NIKI BIOSOLUTIONS, INC.
116 VILLAGE BOULEVARD, SUITE 200

(Street)
PRINCETONNJ08540

(City)(State)(Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/09/2026
3. Issuer Name and Ticker or Trading Symbol
Niki BioSolutions, Inc. [ NIKI ]
Foreign Trading Symbol
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
checkbox checkedOfficer (give title below)Other (specify below)
Chief Financial Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
checkbox checkedForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (1)09/01/2036Common Stock75,000(1)8.83D
Explanation of Responses:
1. Represents options to purchase an aggregate of 75,000 shares of the Issuer's common stock, granted on September 1, 2026, at an exercise price of $8.83 per share, of which (i) 15,000 vest upon the filing of the Issuer's first full Annual Report following the merger, (ii) 20,000 vest in equal quarterly installments over eight quarters following September 1, 2026, (iii) 15,000 vest upon the Issuer raising an aggregate of $5,000,000 in cumulative capital investments, and (iv) 25,000 vest upon a change in control of the Issuer. All unvested options will accelerate and vest upon a change in control, subject to the terms of the applicable equity incentive plan.
/s/ Thomas John Freeburg11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.